Related Experiment Video

Updated: Aug 17, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular

Sana M Al-Khatib1, Gillian D Sanders, Daniel B Mark

  • 1The Duke Clinical Research Institute, Durham, NC 27715, USA. alkha001@mc.duke.edu

American Heart Journal
|June 25, 2005
PubMed

Insights

Implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT) effectiveness in specific patient groups requires further study. Experts convened to review evidence on ICD for sudden cardiac death prevention and CRT for heart failure survival.

Area of Science:

  • Cardiovascular Medicine
  • Health Policy
  • Biostatistics

Background:

  • Implantable cardioverter defibrillator (ICD) therapy improves survival in patients with left ventricular dysfunction.
  • Cardiac resynchronization therapy (CRT) shows benefits in hemodynamics and quality of life for heart failure patients.
  • Uncertainty remains regarding the impact of ICD therapy on specific subgroups and CRT's effect on survival and quality of life.

Purpose of the Study:

  • To review and discuss clinical trial evidence on ICD therapy for primary prevention of sudden cardiac death.
  • To evaluate the effect of CRT on survival and quality of life in patients with congestive heart failure.
  • To address uncertainties surrounding the effectiveness of ICD and CRT in defined patient populations.

Main Methods:

  • Convened an ad hoc group of experts in cardiovascular medicine, biostatistics, economics, and health policy.
  • Included representatives from regulatory and funding agencies (FDA, CMS, AHRQ) and the device industry.
  • Reviewed available clinical trial evidence and expert discussions on ICD and CRT therapies.

Main Results:

  • Evidence on ICD therapy's effectiveness in specific patient subgroups requires further clarification.
  • The impact of CRT on patient survival and the extent of quality of life improvements remain areas of ongoing investigation.
  • The meeting summarized existing evidence and expert discussions, highlighting areas needing further research.

Conclusions:

  • Further research is needed to fully understand the effectiveness of ICD therapy in diverse patient subgroups.
  • The long-term survival benefits and quality of life impact of CRT require continued evaluation.
  • The review highlighted critical knowledge gaps in the application of advanced cardiac therapies.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...